UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 423,261 Shares of AtriCure, Inc. $ATRC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 76.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 131,853 shares of the medical device company’s stock after selling 423,261 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in AtriCure were worth $3,689,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in shares of AtriCure during the second quarter worth about $125,198,000. Bank of America Corp DE acquired a new stake in AtriCure during the 2nd quarter valued at approximately $24,465,000. Grandeur Peak Global Advisors LLC bought a new position in AtriCure during the 2nd quarter worth approximately $16,435,000. Osterweis Capital Management Inc. bought a new position in AtriCure during the 2nd quarter worth approximately $14,028,000. Finally, Marshall Wace LLP raised its holdings in AtriCure by 63.4% during the 4th quarter. Marshall Wace LLP now owns 913,453 shares of the medical device company’s stock worth $36,136,000 after purchasing an additional 354,281 shares during the last quarter. Institutional investors and hedge funds own 99.11% of the company’s stock.

Insiders Place Their Bets

In other AtriCure news, Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $38.80, for a total value of $138,283.20. Following the completion of the sale, the director directly owned 22,809 shares in the company, valued at approximately $884,989.20. This trade represents a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Karl Dahlquist sold 9,370 shares of AtriCure stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider directly owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. This trade represents a 9.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 61,379 shares of company stock valued at $2,557,552. 4.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on ATRC shares. Piper Sandler upped their price objective on shares of AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Weiss Ratings raised shares of AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Raymond James Financial set a $52.00 target price on shares of AtriCure in a report on Tuesday, July 21st. UBS Group cut their price target on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Citigroup reiterated a “market outperform” rating on shares of AtriCure in a report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.00.

AtriCure Price Performance

Shares of ATRC opened at $53.03 on Thursday. The firm has a market cap of $2.70 billion, a PE ratio of 252.54 and a beta of 1.26. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $55.72. The business’s 50 day moving average price is $41.54 and its two-hundred day moving average price is $33.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities analysts anticipate that AtriCure, Inc. will post 0.29 EPS for the current year.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.